Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9603 posts found.

EDC is Now – The Changing

January 5, 2011 Research and Development

Clinical research is rapidly moving toward the electronic environment as more  han half of all studies are conducted utilizing EDC, …
Feature
Thought Leadership

GSK’s Dr Anne Phillips moves to Novo Nordisk

January 4, 2011 Research and Development, Sales and Marketing Dr Anne Phillips, Novo Nordisk, apppointment, research and development, sales and marketing

Novo Nordisk has appointed Dr Anne Phillips as vice president for clinical, medical and regulatory affairs for North America. She …
Appointment

Achieve More in Phase I Studies

January 4, 2011 Research and Development

Some individuals believe not much has changed in Phase 1 dose escalation studies. A recent review1 that looked at 105 …
Feature
Thought Leadership
Novartis Holly Springs

Novartis adds R&D unit to new vaccines plant

December 31, 2010 Manufacturing and Production, Research and Development Novartis, pharma manufacturing, vaccines

Swiss drugmaker Novartis is planning to spend $36 million to set up an R&D laboratory on the site of its …
News

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …
News

2010: Pharma’s year in review

December 23, 2010 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2010, Avandia, China, European healthcare spending, GSK, Obama, year in review

2010 saw a harsh new economic reality dominate decisions in the US and Europe, but pharma seized on opportunities in …
Feature

Gilead set to acquire Arresto for $225 million

December 23, 2010 Research and Development AB0024, Arresto, Cancer, Gilead, advanced solid tumours, ambrisentan, fibrotic diseases, idiopathic pulmonary fibrosis

Gilead Sciences is set to acquire fellow California, US-based biotech Arresto for $225 million to bolster its early stage pipeline. …
News

AstraZeneca takes $445m hit to halt motavizumab

December 22, 2010 Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus

AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …
News

Novartis blood cancer drug impresses in late stage trial

December 22, 2010 Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug

Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …
News

Novo to develop oral insulin

December 22, 2010 Research and Development Emisphere, Novo Nordisk, diabetes, insulin, oral insulin, type I diabetes

Novo Nordisk is to develop an oral formulation of insulin with US biotech company Emisphere Technologies. The New Jersey-based biotech …
News

BMS licences phase II HIV compound festinavir

December 22, 2010 Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor

Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …
News

Novartis makes $500m investment in Russia

December 21, 2010 Manufacturing and Production, Research and Development Novartis, Russia, pharma manufacturing

Novartis is planning to invest $500 million in Russia over the next five years, in a programme which will include …
News

Biogen Idec buys neurodegenerative disease rights

December 21, 2010 Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases

Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …
News

Contract research news in brief

December 20, 2010 Research and Development Biomodels, CIT, Charles River Laboratories, Dedicated Phase I, INC Research, PPD

Our round-up of recent development in the contract research sector includes updates from Charles River, CIT/Biomodels, INC Research, PPD and …
News
AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor)

FDA delays approval of AstraZeneca’s Brilinta

December 20, 2010 Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome

US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …
News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026